What happened with TAK today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Gastrointestinal medicines and therapies made from donated human plasma are Takeda’s largest revenue lines. Its best-selling medicine, ENTYVIO, treats ulcerative colitis and Crohn’s disease. Its plasma business turns collected plasma into medicines, including immunoglobulin therapies such as GAMMAGARD LIQUID/KIOVIG and HYQVIA. Takeda also sells treatments for rare diseases, cancer and neurological conditions, as well as vaccines.
Takeda receives most of its revenue from medicine sales to customers including wholesale distributors, retail chains and purchasing groups. McKesson Group and Cencora Group each account for a substantial share of sales. Most revenue comes from outside Japan, and the United States is its largest market. Insurers and public healthcare systems influence patient access and the prices Takeda can receive through reimbursement decisions and price controls.
The business depends on obtaining and maintaining regulatory approvals and developing new medicines to replace sales lost when patent or regulatory protection ends and cheaper competitors enter. Approved medicines remain subject to safety monitoring, and regulators can limit their use or withdraw approval. The plasma business also depends on donors and outside plasma suppliers, while manufacturing relies on both Takeda’s own plants and contractors.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Takeda’s results depend heavily on ENTYVIO and plasma-derived medicines, where plasma supply is critical and CSL is a major rival alongside Grifols.
Grifols and Takeda compete to sell medicines made from human plasma, so both depend on plasma collection and processing capacity. Watch Grifols’ immunoglobulin and albumin business and its capacity to collect plasma and extract its proteins—the same products and supply constraints matter to Takeda.
AbbVie competes with Takeda’s top-selling ENTYVIO for inflammatory bowel disease patients, but also buys leuprorelin from Takeda. That supply relationship carries a separate risk: a temporary shortage led to a court award of $505 million including interest against Takeda.
Johnson & Johnson’s inflammatory bowel disease medicines compete directly with Takeda’s top-selling ENTYVIO. Its sales of treatments for these patients are more relevant to Takeda than its broader prescription-medicine business, which supplies wholesalers, hospitals and other healthcare providers.
Pfizer competes with Takeda for inflammatory bowel disease patients, but the two also share ADCETRIS development costs and sell it in separate markets. Pfizer sells ADCETRIS in the U.S. and Canada; Takeda sells it elsewhere and pays Pfizer a share of those sales as royalties, so growth in Takeda’s territories benefits both.
Sanofi competes with Takeda to supply rare-disease treatments, including medicines for hemophilia and Fabry disease. Its Dupixent also competes with Takeda’s EOHILIA, giving Takeda investors another product rivalry to watch.
Bristol Myers Squibb’s Zeposia competes with Takeda’s ENTYVIO for inflammatory bowel disease patients. Zeposia sales are the specific line to watch for competition facing Takeda’s largest-selling medicine, rather than Bristol Myers Squibb’s overall drug revenue.
Eli Lilly’s Omvoh competes with Takeda’s ENTYVIO for inflammatory bowel disease patients. Watch Omvoh’s uptake among those patients: it puts Lilly’s ability to win business against Takeda’s top-selling medicine in focus.
Takeda uses Halozyme’s licensed enzyme to help HYQVIA disperse and absorb under the skin, and also has exclusive access to its ENHANZE technology for vedolizumab. Halozyme earns fees and sales-based royalties from drug-company partners, so HYQVIA uptake links Takeda’s immunoglobulin growth to Halozyme’s licensed technology.
Takeda’s planned oveporexton launch, subject to regulatory approval, could challenge Jazz Pharmaceuticals’ established Xywav and Xyrem narcolepsy treatments. Watch Jazz’s news on payer coverage and treatment choices for narcolepsy patients, which shows the competition Takeda would face entering this market.
Protagonist Therapeutics and Takeda share the economics of developing and selling rusfertide, with equal U.S. profit-and-loss sharing unless Protagonist opts out. Watch that opt-out decision: it would give Takeda an exclusive worldwide license and replace the current arrangement with worldwide sales royalties and contingent payments to Protagonist.
Takeda is increasing late-stage investment in elritercept, which Keros Therapeutics licensed to it for development, manufacture and sale worldwide except mainland China, Hong Kong and Macau. Keros’ elritercept milestone news can mark progress in that investment; approval and sales would also trigger royalties payable by Takeda.
HUTCHMED and Takeda sell the same colorectal cancer medicine in separate territories: HUTCHMED developed fruquintinib and markets it in China, while Takeda licenses it as FRUZAQLA outside mainland China, Hong Kong and Macau. HUTCHMED’s fruquintinib clinical results are relevant to that shared medicine, but its China sales are separate from Takeda’s FRUZAQLA revenue.
Phathom Pharmaceuticals licenses the acid-suppressing medicine vonoprazan from Takeda for the U.S., Europe and Canada and has obligations to buy drug substance from Takeda. Its U.S. VOQUEZNA sales show uptake of the same molecule in a separate market, not sales of Takeda’s TAKECAB/VOCINTI business.
Takeda Pharmaceutical Company Limited earningsThis company
Takeda’s growth and launch products now make up more than half of revenue, and its report will show whether they can offset continued U.S. generic pressure on VYVANSE.
Read growth and launch product sales alongside neuroscience sales, especially VYVANSE/ELVANSE. Continued growth in the first while the second declines less would show newer products are replacing lost sales; slowing growth alongside further neuroscience declines would show the replacement is not keeping pace and Takeda’s overall growth remains under pressure.
